<p>随着全球市场在利率预期和持续的人工智能热潮中航行，道琼斯指数、标准普尔 500 指数和纳斯达克综合指数等主要指数已达到历史新高。在这种乐观和经济变革的背景下，内部持股比例高的成长型公司通常表明强大的内部信心和与股东利益的一致性，使其对寻求在波动市场环境中获得稳定的投资者具有吸引力。</p>
<h3>全球内部持股比例高的十大成长型公司</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>内部持股比例</strong></td>
<td><strong>盈利增长</strong></td>
</tr>
<tr>
<td>Seers Technology (KOSDAQ:A458870)</td>
<td>33.9%</td>
<td>84.6%</td>
</tr>
<tr>
<td>Pharma Mar (BME:PHM)</td>
<td>11.8%</td>
<td>44.2%</td>
</tr>
<tr>
<td>Novoray (SHSE:688300)</td>
<td>23.6%</td>
<td>30.3%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>35.5%</td>
<td>33.9%</td>
</tr>
<tr>
<td>KebNi (OM:KEBNI B)</td>
<td>38.4%</td>
<td>63.7%</td>
</tr>
<tr>
<td>Gold Circuit Electronics (TWSE:2368)</td>
<td>31.4%</td>
<td>35.2%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>11.8%</td>
<td>50.7%</td>
</tr>
<tr>
<td>Elliptic Laboratories (OB:ELABS)</td>
<td>24.4%</td>
<td>97.5%</td>
</tr>
<tr>
<td>CD Projekt (WSE:CDR)</td>
<td>29.7%</td>
<td>43.5%</td>
</tr>
<tr>
<td>Ascentage Pharma Group International (SEHK:6855)</td>
<td>12.8%</td>
<td>91.9%</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们内部持股比例高的快速成长全球公司筛选器中的 844 只股票的完整列表。</p>
<p>我们将查看筛选工具中的一些最佳选择。</p>
<h2>北京海博思创科技 (SHSE:688411)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 北京海博思创科技有限公司专注于在中国、欧洲、北美和澳大利亚设计、开发、集成和运营能源存储电站，市值为 328.7 亿人民币。</p>
<p><strong>运营：</strong> 收入细分（单位：百万人民币）：</p>
<p><strong>内部持股比例：</strong> 22.6%</p>
<p><strong>盈利增长预测：</strong> 年均 26.9%。</p>
<p>北京海博思创科技有望实现强劲增长，预计收入年均增长 29.4%，超过市场平均水平。盈利也预计将显著增长，年均增长 26.88%。该公司最近与北京第四范式科技的合资企业旨在利用人工智能提升能源存储的技术优势和市场覆盖。尽管股价波动较大，但战略联盟可能在没有近期显著内部交易活动的情况下增强长期前景。</p>
<ul>
<li>通过阅读我们的分析师估计报告，深入了解北京海博思创科技的表现。</li>
<li>我们精心准备的估值报告显示，北京海博思创科技的股价可能过高。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3bfd9198-7ed0-45a8-8819-04c19d1aa84b/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3bfd9198-7ed0-45a8-8819-04c19d1aa84b/chart/ownership-breakdown"/></p>
<p>截至 2025 年 9 月的 SHSE:688411 股权结构</p>
<h2>源杰科技 (SHSE:688498)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 源杰科技有限公司（股票代码：SHSE:688498）在半导体行业运营，市值为 319.5 亿人民币。</p>
<p><strong>运营：</strong> 源杰科技的收入来自半导体行业的各个细分领域。</p>
<p><strong>内部持股比例：</strong> 28.0%</p>
<p><strong>盈利增长预测：</strong> 年均 68.2%。</p>
<p>源杰科技有望实现显著增长，预计盈利年均增长 68.16%，超过中国市场。收入也预计年均增长 42%。最近的盈利报告显示，净收入从去年 1075 万人民币增长至 4626 万人民币。尽管股价波动较大，且未来的股本回报率预测较低，但没有近期的内部交易表明对未来表现的信心。</p>
<ul>
<li>在这份增长报告中解锁我们对源杰科技股票分析的全面见解。</li>
<li>我们的估值报告显示，源杰科技可能被高估。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/e1b67cd8-756e-41ed-a2b2-44d64189c77d/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/e1b67cd8-756e-41ed-a2b2-44d64189c77d/chart/ownership-breakdown"/></p>
<p>截至 2025 年 9 月的 SHSE:688498 股权结构</p>
<h2>内蒙古富瑞医学科技 (SZSE:300049)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 内蒙古富瑞医学科技有限公司在医学科技行业运营，专注于开发和制造医疗产品，市值为 181.6 亿人民币。</p>
<p><strong>运营：</strong> 内蒙古富瑞医学科技有限公司通过专注于开发和制造医疗产品来产生收入。</p>
<p><strong>内部持股比例：</strong> 16.1%</p>
<p><strong>盈利增长预测：</strong> 年均 45%。</p>
<p>内蒙古富瑞医学科技有望实现显著增长，预计盈利年均增长 45%，超过中国市场的预测。收入预计年均增长 22.1%，尽管最近的报告显示净收入从 7536 万人民币下降至 5193 万人民币。尽管股价波动较大，且未来的股本回报率预测较低为 15.1%，但没有内部交易活动表明内部信心稳定。</p>
<ul>
<li>在我们的盈利增长报告中更深入地了解内蒙古富瑞医学科技的潜力。</li>
<li>根据我们的估值报告，内蒙古富瑞医学科技的股价可能偏高。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b77fa0ad-6c66-4515-9cd9-e43b415df394/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b77fa0ad-6c66-4515-9cd9-e43b415df394/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 9 月的 SZSE:300049 盈利和收入增长</p>
<h2>抓住机会</h2>
<ul>
<li>点击这里解锁我们 844 家快速成长全球公司内部持股比例高的全面列表。</li>
<li>准备好采取不同的方法吗？发现 8 家在 COVID 后生存并蓬勃发展的公司，它们具备生存特朗普关税的正确要素。</li>
</ul>
<p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不意图提供财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。该分析仅考虑内部人士直接持有的股票，不包括通过其他工具（如公司和/或信托实体）间接持有的股票。所有引用的预测收入和收益增长率均以年化（每年）增长率的形式表示，时间范围为 1-3 年。</em></p>

海博思创

源杰科技

<p>随着全球市场在利率预期和人工智能热潮中创下历史新高，拥有高内部持股的成长型公司正吸引投资者的关注。值得注意的公司包括北京海博思创、源杰科技和内蒙古富瑞医疗科技，这些公司都显示出良好的盈利增长预期。尽管股价波动，但内部持股表明了强大的内部信心。文章强调了内部持股在评估公司稳定性和增长潜力中的重要性，同时提供了一份包含 844 家高内部持股快速增长公司的名单</p>

<p>As global markets navigate through interest rate expectations and the ongoing artificial intelligence boom, major indices such as the Dow Jones, S&amp;P 500, and Nasdaq Composite have reached record highs. Amid this backdrop of optimism and economic shifts, growth companies with high insider ownership often signal strong internal confidence and alignment with shareholder interests, making them appealing to investors seeking stability in a fluctuating market environment.</p>
<div class="lb-trans"><p>随着全球市场在利率预期和持续的人工智能热潮中航行，道琼斯指数、标准普尔 500 指数和纳斯达克综合指数等主要指数已达到历史新高。在这种乐观和经济变革的背景下，内部持股比例高的成长型公司通常表明强大的内部信心和与股东利益的一致性，使其对寻求在波动市场环境中获得稳定的投资者具有吸引力。</p>
</div><h3>Top 10 Growth Companies With High Insider Ownership Globally</h3>
<div class="lb-trans"><h3>全球内部持股比例高的十大成长型公司</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Insider Ownership</strong></td>
<td><strong>Earnings Growth</strong></td>
</tr>
<tr>
<td>Seers Technology (KOSDAQ:A458870)</td>
<td>33.9%</td>
<td>84.6%</td>
</tr>
<tr>
<td>Pharma Mar (BME:PHM)</td>
<td>11.8%</td>
<td>44.2%</td>
</tr>
<tr>
<td>Novoray (SHSE:688300)</td>
<td>23.6%</td>
<td>30.3%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>35.5%</td>
<td>33.9%</td>
</tr>
<tr>
<td>KebNi (OM:KEBNI B)</td>
<td>38.4%</td>
<td>63.7%</td>
</tr>
<tr>
<td>Gold Circuit Electronics (TWSE:2368)</td>
<td>31.4%</td>
<td>35.2%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>11.8%</td>
<td>50.7%</td>
</tr>
<tr>
<td>Elliptic Laboratories (OB:ELABS)</td>
<td>24.4%</td>
<td>97.5%</td>
</tr>
<tr>
<td>CD Projekt (WSE:CDR)</td>
<td>29.7%</td>
<td>43.5%</td>
</tr>
<tr>
<td>Ascentage Pharma Group International (SEHK:6855)</td>
<td>12.8%</td>
<td>91.9%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>内部持股比例</strong></td>
<td><strong>盈利增长</strong></td>
</tr>
<tr>
<td>Seers Technology (KOSDAQ:A458870)</td>
<td>33.9%</td>
<td>84.6%</td>
</tr>
<tr>
<td>Pharma Mar (BME:PHM)</td>
<td>11.8%</td>
<td>44.2%</td>
</tr>
<tr>
<td>Novoray (SHSE:688300)</td>
<td>23.6%</td>
<td>30.3%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>35.5%</td>
<td>33.9%</td>
</tr>
<tr>
<td>KebNi (OM:KEBNI B)</td>
<td>38.4%</td>
<td>63.7%</td>
</tr>
<tr>
<td>Gold Circuit Electronics (TWSE:2368)</td>
<td>31.4%</td>
<td>35.2%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>11.8%</td>
<td>50.7%</td>
</tr>
<tr>
<td>Elliptic Laboratories (OB:ELABS)</td>
<td>24.4%</td>
<td>97.5%</td>
</tr>
<tr>
<td>CD Projekt (WSE:CDR)</td>
<td>29.7%</td>
<td>43.5%</td>
</tr>
<tr>
<td>Ascentage Pharma Group International (SEHK:6855)</td>
<td>12.8%</td>
<td>91.9%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 844 stocks from our Fast Growing Global Companies With High Insider Ownership screener.</p>
<div class="lb-trans"><p>点击这里查看我们内部持股比例高的快速成长全球公司筛选器中的 844 只股票的完整列表。</p>
</div><p>We're going to check out a few of the best picks from our screener tool.</p>
<div class="lb-trans"><p>我们将查看筛选工具中的一些最佳选择。</p>
</div><h2>Beijing HyperStrong Technology (SHSE:688411)</h2>
<div class="lb-trans"><h2>北京海博思创科技 (SHSE:688411)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Beijing HyperStrong Technology Co., Ltd. specializes in the design, development, integration, and operation of energy storage power stations across China, Europe, North America, and Australia with a market cap of CN¥32.87 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 北京海博思创科技有限公司专注于在中国、欧洲、北美和澳大利亚设计、开发、集成和运营能源存储电站，市值为 328.7 亿人民币。</p>
</div><p><strong>Operations:</strong> Revenue Segments (in millions of CN¥):</p>
<div class="lb-trans"><p><strong>运营：</strong> 收入细分（单位：百万人民币）：</p>
</div><p><strong>Insider Ownership:</strong> 22.6%</p>
<div class="lb-trans"><p><strong>内部持股比例：</strong> 22.6%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 26.9% p.a.</p>
<div class="lb-trans"><p><strong>盈利增长预测：</strong> 年均 26.9%。</p>
</div><p>Beijing HyperStrong Technology is poised for robust growth, with revenue expected to increase by 29.4% annually, surpassing market averages. Earnings are also forecasted to grow significantly at 26.88% per year. The company's recent joint venture with Beijing Fourth Paradigm Technology aims to leverage AI in energy storage, enhancing its technological edge and market reach. Despite high volatility in share price, the strategic alliance could bolster long-term prospects without substantial insider trading activity noted recently.</p>
<div class="lb-trans"><p>北京海博思创科技有望实现强劲增长，预计收入年均增长 29.4%，超过市场平均水平。盈利也预计将显著增长，年均增长 26.88%。该公司最近与北京第四范式科技的合资企业旨在利用人工智能提升能源存储的技术优势和市场覆盖。尽管股价波动较大，但战略联盟可能在没有近期显著内部交易活动的情况下增强长期前景。</p>
</div><ul>
<li>Get an in-depth perspective on Beijing HyperStrong Technology's performance by reading our analyst estimates report here.</li>
<li>Our expertly prepared valuation report Beijing HyperStrong Technology implies its share price may be too high.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过阅读我们的分析师估计报告，深入了解北京海博思创科技的表现。</li>
<li>我们精心准备的估值报告显示，北京海博思创科技的股价可能过高。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3bfd9198-7ed0-45a8-8819-04c19d1aa84b/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/3bfd9198-7ed0-45a8-8819-04c19d1aa84b/chart/ownership-breakdown"/></p>
<p>SHSE:688411 Ownership Breakdown as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月的 SHSE:688411 股权结构</p>
</div><h2>Yuanjie Semiconductor Technology (SHSE:688498)</h2>
<div class="lb-trans"><h2>源杰科技 (SHSE:688498)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Yuanjie Semiconductor Technology Co., Ltd. (ticker: SHSE:688498) operates in the semiconductor industry and has a market capitalization of CN¥31.95 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 源杰科技有限公司（股票代码：SHSE:688498）在半导体行业运营，市值为 319.5 亿人民币。</p>
</div><p><strong>Operations:</strong> Yuanjie Semiconductor Technology's revenue is derived from various segments within the semiconductor industry.</p>
<div class="lb-trans"><p><strong>运营：</strong> 源杰科技的收入来自半导体行业的各个细分领域。</p>
</div><p><strong>Insider Ownership:</strong> 28.0%</p>
<div class="lb-trans"><p><strong>内部持股比例：</strong> 28.0%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 68.2% p.a.</p>
<div class="lb-trans"><p><strong>盈利增长预测：</strong> 年均 68.2%。</p>
</div><p>Yuanjie Semiconductor Technology is set for substantial growth, with earnings projected to rise by 68.16% annually, outpacing the Chinese market. Revenue is also expected to grow at a robust 42% per year. Recent earnings reports show significant improvements, with net income reaching CNY 46.26 million from CNY 10.75 million last year. Despite high share price volatility and low forecasted return on equity, no recent insider trading suggests confidence in future performance.</p>
<div class="lb-trans"><p>源杰科技有望实现显著增长，预计盈利年均增长 68.16%，超过中国市场。收入也预计年均增长 42%。最近的盈利报告显示，净收入从去年 1075 万人民币增长至 4626 万人民币。尽管股价波动较大，且未来的股本回报率预测较低，但没有近期的内部交易表明对未来表现的信心。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of Yuanjie Semiconductor Technology stock in this growth report.</li>
<li>Our valuation report here indicates Yuanjie Semiconductor Technology may be overvalued.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这份增长报告中解锁我们对源杰科技股票分析的全面见解。</li>
<li>我们的估值报告显示，源杰科技可能被高估。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/e1b67cd8-756e-41ed-a2b2-44d64189c77d/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/e1b67cd8-756e-41ed-a2b2-44d64189c77d/chart/ownership-breakdown"/></p>
<p>SHSE:688498 Ownership Breakdown as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月的 SHSE:688498 股权结构</p>
</div><h2>Inner Mongolia Furui Medical Science (SZSE:300049)</h2>
<div class="lb-trans"><h2>内蒙古富瑞医学科技 (SZSE:300049)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Inner Mongolia Furui Medical Science Co., Ltd. operates in the medical science industry with a focus on developing and manufacturing medical products, and it has a market cap of CN¥18.16 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 内蒙古富瑞医学科技有限公司在医学科技行业运营，专注于开发和制造医疗产品，市值为 181.6 亿人民币。</p>
</div><p><strong>Operations:</strong> Inner Mongolia Furui Medical Science Co., Ltd. generates revenue through its focus on developing and manufacturing medical products.</p>
<div class="lb-trans"><p><strong>运营：</strong> 内蒙古富瑞医学科技有限公司通过专注于开发和制造医疗产品来产生收入。</p>
</div><p><strong>Insider Ownership:</strong> 16.1%</p>
<div class="lb-trans"><p><strong>内部持股比例：</strong> 16.1%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 45% p.a.</p>
<div class="lb-trans"><p><strong>盈利增长预测：</strong> 年均 45%。</p>
</div><p>Inner Mongolia Furui Medical Science is poised for significant growth, with earnings expected to increase by 45% annually, surpassing the Chinese market's forecast. Revenue is projected to grow at 22.1% per year, though recent reports show a decline in net income from CNY 75.36 million to CNY 51.93 million compared to last year. Despite volatile share prices and a low future return on equity of 15.1%, no insider trading activity indicates stable internal confidence.</p>
<div class="lb-trans"><p>内蒙古富瑞医学科技有望实现显著增长，预计盈利年均增长 45%，超过中国市场的预测。收入预计年均增长 22.1%，尽管最近的报告显示净收入从 7536 万人民币下降至 5193 万人民币。尽管股价波动较大，且未来的股本回报率预测较低为 15.1%，但没有内部交易活动表明内部信心稳定。</p>
</div><ul>
<li>Take a closer look at Inner Mongolia Furui Medical Science's potential here in our earnings growth report.</li>
<li>According our valuation report, there's an indication that Inner Mongolia Furui Medical Science's share price might be on the expensive side.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我们的盈利增长报告中更深入地了解内蒙古富瑞医学科技的潜力。</li>
<li>根据我们的估值报告，内蒙古富瑞医学科技的股价可能偏高。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b77fa0ad-6c66-4515-9cd9-e43b415df394/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/b77fa0ad-6c66-4515-9cd9-e43b415df394/chart/earnings-and-revenue-growth"/></p>
<p>SZSE:300049 Earnings and Revenue Growth as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月的 SZSE:300049 盈利和收入增长</p>
</div><h2>Taking Advantage</h2>
<div class="lb-trans"><h2>抓住机会</h2>
</div><ul>
<li>Unlock our comprehensive list of 844 Fast Growing Global Companies With High Insider Ownership by clicking here.</li>
<li>Ready For A Different Approach? Uncover 8 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里解锁我们 844 家快速成长全球公司内部持股比例高的全面列表。</li>
<li>准备好采取不同的方法吗？发现 8 家在 COVID 后生存并蓬勃发展的公司，它们具备生存特朗普关税的正确要素。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p>
<div class="lb-trans"><p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不意图提供财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。该分析仅考虑内部人士直接持有的股票，不包括通过其他工具（如公司和/或信托实体）间接持有的股票。所有引用的预测收入和收益增长率均以年化（每年）增长率的形式表示，时间范围为 1-3 年。</em></p>
</div>

全球增长型股票受到内部人士高度信任